Sign in or create an account to add this stock to your watchlist.
About Abaxis (NASDAQ:ABAX)
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Industry, Sector and Symbol
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.02
Quick Ratio5.02
Price-To-Earnings
Trailing P/E Ratio64.54
Forward P/E Ratio56.26
P/E Growth5.16
Sales & Book Value
Annual Sales$244.70 million
Price / Sales7.78
Cash Flow$1.7142 per share
Price / Cash48.57
Book Value$12.81 per share
Price / Book6.50
Profitability
EPS (Most Recent Fiscal Year)$1.29
Net Income$27.17 million
Net Margins11.11%
Return on Equity10.65%
Return on Assets9.12%
Miscellaneous
Employees656
Outstanding Shares22,870,000
Abaxis (NASDAQ:ABAX) Frequently Asked Questions
What is Abaxis' stock symbol?
Abaxis trades on the NASDAQ under the ticker symbol "ABAX."
How often does Abaxis pay dividends? What is the dividend yield for Abaxis?
Abaxis declared a quarterly dividend on Thursday, April 26th. Shareholders of record on Friday, June 1st will be paid a dividend of $0.18 per share on Friday, June 15th. This represents a $0.72 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, May 31st. This is a boost from Abaxis's previous quarterly dividend of $0.16. View Abaxis' Dividend History.
How will Abaxis' stock buyback program work?
Abaxis declared that its Board of Directors has initiated a stock repurchase program on Wednesday, October 25th 2017, which authorizes the company to repurchase $21,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's board believes its stock is undervalued.
How were Abaxis' earnings last quarter?
Abaxis Inc (NASDAQ:ABAX) posted its quarterly earnings results on Thursday, April, 26th. The medical research company reported $0.42 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.10. The medical research company had revenue of $67.90 million for the quarter, compared to analyst estimates of $66.02 million. Abaxis had a net margin of 11.11% and a return on equity of 10.65%. The business's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 EPS. View Abaxis' Earnings History.
When is Abaxis' next earnings date?
What price target have analysts set for ABAX?
9 Wall Street analysts have issued twelve-month target prices for Abaxis' shares. Their predictions range from $48.00 to $65.00. On average, they anticipate Abaxis' share price to reach $58.3333 in the next year. View Analyst Ratings for Abaxis.
Who are some of Abaxis' key competitors?
Some companies that are related to Abaxis include Cubic (CUB), MTS Systems (MTSC), Nanometrics (NANO), Faro Technologies (FARO), Oxford Instruments (OXINF), Geospace Technologies (GEOS), Cemtrex (CETX), Image Sensing Systems (ISNS), Midwest Energy Emissions (MEEC), Mikros Systems (MKRS), Sierra Monitor (SRMC), Mechanical Technology (MKTY) and Visualant (VSUL).
Who are Abaxis' key executives?
Abaxis' management team includes the folowing people:
- Mr. Clinton H. Severson, Chairman and Chief Exec. Officer (Age 70)
- Mr. Donald P. Wood, Pres & COO (Age 66)
- Mr. Ross Taylor Jr., CFO, Principal Accounting Officer, VP of Fin. & Sec. (Age 55)
- Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
- Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)
Has Abaxis been receiving favorable news coverage?
Press coverage about ABAX stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a news impact score of 0.06 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.53 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Abaxis' major shareholders?
Abaxis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (16.82%), BlackRock Inc. (13.92%), Dimensional Fund Advisors LP (3.13%), Wells Fargo & Company MN (2.96%), Royal Bank of Canada (1.81%) and Copeland Capital Management LLC (1.45%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.
Which major investors are selling Abaxis stock?
ABAX stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Echo Street Capital Management LLC, Royal Bank of Canada, Tiverton Asset Management LLC, Spark Investment Management LLC, Glen Harbor Capital Management LLC, Rhumbline Advisers and JPMorgan Chase & Co.. Company insiders that have sold Abaxis company stock in the last year include Achim Henkel, Craig Tockman, Donald Peter Wood, Kenneth Aron, Michael D Casey and Prithipal Singh. View Insider Buying and Selling for Abaxis.
Which major investors are buying Abaxis stock?
ABAX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Rockefeller Capital Management L.P., Kayne Anderson Rudnick Investment Management LLC, Pier Capital LLC, WINTON GROUP Ltd, Federated Investors Inc. PA, Wells Fargo & Company MN and Millennium Management LLC. View Insider Buying and Selling for Abaxis.
How do I buy shares of Abaxis?
Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abaxis' stock price today?
One share of ABAX stock can currently be purchased for approximately $83.26.
How big of a company is Abaxis?
Abaxis has a market capitalization of $1.90 billion and generates $244.70 million in revenue each year. The medical research company earns $27.17 million in net income (profit) each year or $1.29 on an earnings per share basis. Abaxis employs 656 workers across the globe.
How can I contact Abaxis?
Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]
MarketBeat Community Rating for Abaxis (ABAX)
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abaxis (NASDAQ:ABAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Abaxis in the last 12 months. Their average twelve-month price target is $58.3333, suggesting that the stock has a possible downside of 29.94%. The high price target for ABAX is $65.00 and the low price target for ABAX is $48.00. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $58.3333 | $57.8750 | $56.6250 | $47.6250 |
| Price Target Upside: | 29.94% downside | 30.56% downside | 11.79% downside | 1.25% downside |
Abaxis (NASDAQ:ABAX) Consensus Price Target History
Abaxis (NASDAQ:ABAX) Analyst Ratings History
Show:
(Data available from 6/17/2016 forward)
Abaxis (NASDAQ:ABAX) Dividend Information
Abaxis pays an annual dividend of $0.72 per share, with a dividend yield of 0.86%. ABAX's most recent quarterly dividend payment was Friday, June 15. Abaxis pays out 55.81% of its earnings out as a dividend.
| Most Recent Dividend: | 6/15/2018 |
| Annual Dividend: | $0.72 |
| Dividend Yield: | 0.86% |
| Payout Ratio(s): | 55.81% (Trailing 12 Months of Earnings)
48.65% (Based on This Year's Estimates)
42.11% (Based on Next Year's Estimates)
42.00% (Based on Cash Flow)
|
Abaxis (NASDAQ:ABAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/26/2018 | quarterly | $0.18 | 0.99% | 5/31/2018 | 6/1/2018 | 6/15/2018 |
| 1/25/2018 | quarterly | $0.16 | 0.91% | 2/28/2018 | 3/1/2018 | 3/15/2018 |
| 10/24/2017 | quarterly | $0.16 | 1.28% | 11/30/2017 | 12/1/2017 | 12/15/2017 |
| 7/27/2017 | quarterly | $0.14 | 1.19% | 8/30/2017 | 9/1/2017 | 9/15/2017 |
| 4/27/2017 | quarterly | $0.14 | 1.24% | 5/30/2017 | 6/1/2017 | 6/15/2017 |
| 1/26/2017 | quarterly | $0.14 | 1.13% | 2/27/2017 | 3/1/2017 | 3/15/2017 |
| 10/28/2016 | quarterly | $0.14 | 1.17% | 11/29/2016 | 12/1/2016 | 12/15/2016 |
| 7/21/2016 | quarterly | $0.12 | 1.04% | 8/30/2016 | 9/1/2016 | 9/15/2016 |
| 4/28/2016 | quarterly | $0.12 | 1.06% | 6/1/2016 | 6/3/2016 | 6/17/2016 |
| 1/28/2016 | quarterly | $0.11 | 1.01% | 3/1/2016 | 3/3/2016 | 3/17/2016 |
| 11/3/2015 | quarterly | $0.11 | 0.84% | 12/1/2015 | 12/3/2015 | 12/17/2015 |
| 7/23/2015 | quarterly | $0.11 | 0.9% | 9/1/2015 | 9/3/2015 | 9/17/2015 |
| 4/30/2015 | quarterly | $0.11 | 0.79% | 6/2/2015 | 6/4/2015 | 6/18/2015 |
| 1/30/2015 | quarterly | $0.10 | 0.65% | 2/27/2015 | 3/3/2015 | 3/17/2015 |
| 10/23/2014 | quarterly | $0.10 | 0.82% | 11/13/2014 | 11/17/2014 | 12/16/2014 |
| 7/24/2014 | quarterly | $0.10 | 0.86% | 8/29/2014 | 9/3/2014 | 9/17/2014 |
| 4/24/2014 | quarterly | $0.10 | | 5/30/2014 | 6/3/2014 | 6/17/2014 |
| 12/6/2012 | special | $1.00 | | 12/13/2012 | 12/17/2012 | 12/28/2012 |
(Data available from 1/1/2013 forward)
Abaxis (NASDAQ ABAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 94.50%
Abaxis (NASDAQ ABAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/29/2018 | Achim Henkel | Insider | Sell | 8,000 | $83.00 | $664,000.00 | 70,950 |  |
| 5/22/2018 | Kenneth Aron | Insider | Sell | 1,533 | $83.11 | $127,407.63 | 115,493 | |
| 5/18/2018 | Prithipal Singh | Director | Sell | 20,000 | $83.31 | $1,666,200.00 | 38,400 | |
| 5/8/2018 | Achim Henkel | Director | Sell | 6,000 | $68.06 | $408,360.00 | 83,344 | |
| 3/8/2018 | Michael D Casey | Director | Sell | 5,000 | $71.07 | $355,350.00 | 27,290 | |
| 3/6/2018 | Donald Peter Wood | COO | Sell | 10,000 | $68.99 | $689,900.00 | | |
| 3/6/2018 | Kenneth Aron | Insider | Sell | 1,412 | $69.59 | $98,261.08 | | |
| 3/6/2018 | Prithipal Singh | Director | Sell | 2,000 | $70.25 | $140,500.00 | | |
| 2/27/2018 | Achim Henkel | Insider | Sell | 3,600 | $69.08 | $248,688.00 | 57,650 | |
| 1/31/2018 | Craig Tockman | VP | Sell | 1,650 | $74.33 | $122,644.50 | 10,866 | |
| 1/31/2018 | Prithipal Singh | Director | Sell | 2,000 | $74.63 | $149,260.00 | 44,000 | |
| 5/26/2017 | Achim Henkel | Insider | Sell | 650 | $48.87 | $31,765.50 | 58,950 | |
| 5/8/2017 | Achim Henkel | Director | Sell | 8,650 | $47.75 | $413,037.50 | 68,150 | |
| 2/2/2017 | Richard Bastiani | Director | Sell | 4,000 | $51.12 | $204,480.00 | 49,178 | |
| 12/6/2016 | Clinton Severson | CEO | Sell | 15,000 | $51.35 | $770,250.00 | 562,300 | |
| 12/2/2016 | Kenneth Aron | Insider | Sell | 5,000 | $51.09 | $255,450.00 | 92,151 | |
| 9/9/2016 | Clinton Severson | CEO | Sell | 2,000 | $48.29 | $96,580.00 | 574,691 | |
| 9/8/2016 | Prithipal Singh | Director | Sell | 1,000 | $49.50 | $49,500.00 | 42,500 | |
| 8/25/2016 | Prithipal Singh | Director | Sell | 1,500 | $50.30 | $75,450.00 | 43,500 | |
| 8/24/2016 | Donald Peter Wood | Insider | Sell | 8,500 | $50.21 | $426,785.00 | 52,618 | |
| 6/9/2016 | Richard Bastiani | Director | Sell | 5,000 | $46.75 | $233,750.00 | 54,400 | |
| 5/17/2016 | Achim Henkel | Director | Sell | 5,000 | $44.43 | $222,150.00 | 53,609 | |
| 5/9/2016 | Henk Evenhuis | Director | Sell | 3,000 | $45.00 | $135,000.00 | 15,400 | |
| 2/9/2016 | Vernon E Altman | Director | Buy | 303 | $39.87 | $12,080.61 | 16,303 | |
| 12/8/2015 | Craig Tockman | VP | Sell | 560 | $54.44 | $30,486.40 | 1,189 | |
| 2/9/2015 | Prithipal Singh | Director | Sell | 2,500 | $60.50 | $151,250.00 | | |
| 12/8/2014 | Kenneth Aron | CTO | Sell | 2,000 | $56.68 | $113,360.00 | | |
| 11/25/2014 | Clinton Severson | CEO | Sell | 2,286 | $56.00 | $128,016.00 | | |
| 11/13/2014 | Clinton Severson | CEO | Sell | 10,000 | $55.00 | $550,000.00 | | |
| 11/5/2014 | Clinton Severson | CEO | Sell | 10,000 | $54.00 | $540,000.00 | | |
| 11/3/2014 | Alberto Santa Ines | CFO | Sell | 1,652 | $53.09 | $87,704.68 | | |
| 11/3/2014 | Clinton Severson | CEO | Sell | 5,000 | $53.00 | $265,000.00 | | |
| 10/31/2014 | Clinton Severson | CEO | Sell | 10,000 | $51.50 | $515,000.00 | | |
| 8/12/2014 | Richard Bastiani | Director | Sell | 1,000 | $45.40 | $45,400.00 | | |
| 7/30/2014 | Alberto Santa Ines | CFO | Sell | 10,738 | $47.81 | $513,383.78 | | |
| 7/29/2014 | Alberto Santa Ines | CFO | Sell | 17,293 | $48.01 | $830,236.93 | | |
| 6/5/2014 | Richard Bastiani | Director | Sell | 2,000 | $42.10 | $84,200.00 | | |
| 6/3/2014 | Richard Bastiani | Director | Sell | 4,000 | $41.88 | $167,520.00 | | |
| 5/22/2014 | Achim Henkel | Director | Sell | 8,500 | $41.63 | $353,855.00 | | |
| 5/14/2014 | Henk Evenhuis | Director | Sell | 4,000 | $44.06 | $176,240.00 | 10,400 | |
| 5/1/2014 | Henk Evenhuis | Director | Sell | 4,500 | $41.00 | $184,500.00 | 14,400 | |
| 3/4/2014 | Vladimir Ostoich | VP | Sell | 9,800 | $38.53 | $377,594.00 | 381,987 | |
| 2/24/2014 | Kenneth Aron | CTO | Sell | 1,000 | $38.98 | $38,980.00 | 64,330 | |
| 2/13/2014 | Donald Peter Wood | COO | Sell | 8,864 | $38.50 | $341,264.00 | 20,634 | |
| 6/7/2013 | Clinton Severson | CEO | Sell | 10,000 | $44.50 | $445,000.00 | | |
| 6/7/2013 | Martin Mulroy | Insider | Sell | 14,000 | $44.80 | $627,200.00 | | |
| 5/22/2013 | Kenneth Aron | CTO | Sell | 4,200 | $43.28 | $181,776.00 | | |
| 5/7/2013 | Achim Henkel | Director | Sell | 5,000 | $44.07 | $220,350.00 | | |
| 3/1/2013 | Achim Henkel | Director | Sell | 1,000 | $42.85 | $42,850.00 | | |
| 2/26/2013 | Martin Mulroy | Insider | Sell | 12,000 | $41.84 | $502,080.00 | | |
| 2/5/2013 | Kenneth Aron | CTO | Sell | 40,000 | $44.13 | $1,765,200.00 | | |
| 2/4/2013 | Martin Mulroy | Insider | Sell | 12,000 | $43.97 | $527,640.00 | | |
| 11/23/2012 | Richard Bastiani | Director | Sell | 5,000 | $36.60 | $183,000.00 | | |
(Data available from 1/1/2013 forward)
Abaxis (NASDAQ ABAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Brokerages Expect Abaxis Inc (ABAX) Will Announce Quarterly Sales of $67.84 Million
www.americanbankingnews.com - June 10 at 4:50 AM |
| Abaxis (ABAX) & MTS Systems (MTSC) Financial Survey
www.americanbankingnews.com - June 10 at 3:04 AM |
| $0.35 EPS Expected for Abaxis (ABAX) This Quarter
www.americanbankingnews.com - June 8 at 3:08 AM |
| Abaxis (ABAX) and Trimble (TRMB) Critical Survey
www.americanbankingnews.com - June 7 at 11:19 AM |
 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Abaxis, Inc. - ABAX
www.prnewswire.com - June 5 at 8:52 PM |
| Contrasting Abaxis (ABAX) and Image Sensing Systems (ISNS)
www.americanbankingnews.com - June 5 at 1:24 PM |
| Abaxis (ABAX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 31 at 7:34 PM |
| Abaxis (ABAX) Insider Achim Henkel Sells 8,000 Shares
www.americanbankingnews.com - May 31 at 7:32 PM |
| Abaxis (ABAX) vs. Rockwell Automation (ROK) Head to Head Contrast
www.americanbankingnews.com - May 31 at 7:20 PM |
| Abaxis (ABAX) Rating Reiterated by Sidoti
www.americanbankingnews.com - May 31 at 12:48 PM |
| Head-To-Head Comparison: Abaxis (ABAX) & Cemtrex (CETX)
www.americanbankingnews.com - May 31 at 11:34 AM |
 | Ex-Dividend Reminder: Abaxis, McKesson and Cott
www.nasdaq.com - May 29 at 4:31 PM |
 | Abaxis Inc (NASDAQ:ABAX): Poised For Long-Term Success?
finance.yahoo.com - May 28 at 9:43 AM |
 | Abaxis May Not Receive A New Offer
seekingalpha.com - May 25 at 4:41 PM |
| Abaxis (ABAX) Insider Sells $127,407.63 in Stock
www.americanbankingnews.com - May 24 at 7:50 PM |
| Abaxis (ABAX) vs. Cemtrex (CETX) Head to Head Review
www.americanbankingnews.com - May 24 at 5:21 PM |
| Analysts Expect Abaxis (ABAX) Will Announce Quarterly Sales of $67.84 Million
www.americanbankingnews.com - May 23 at 2:24 AM |
 | Form 4 ABAXIS INC For: May 18 Filed by: SINGH PRITHIPAL
www.streetinsider.com - May 22 at 9:12 AM |
| Abaxis (ABAX) Director Sells $1,666,200.00 in Stock
www.americanbankingnews.com - May 21 at 10:10 PM |
| Abaxis (ABAX) Expected to Post Earnings of $0.35 Per Share
www.americanbankingnews.com - May 21 at 7:14 PM |
| Head-To-Head Review: Abaxis (ABAX) vs. Faro Technologies (FARO)
www.americanbankingnews.com - May 20 at 1:19 AM |
| Reviewing Abaxis (ABAX) and Cubic (CUB)
www.americanbankingnews.com - May 19 at 3:37 PM |
| Robbins Arroyo LLP: Acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. (ZTS) May Not Be in Shareholders' Best Interests
finance.yahoo.com - May 19 at 9:16 AM |
 | INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Abaxis, Inc. to Zoetis Inc. is Fair to Shareholders
www.businesswire.com - May 18 at 4:40 PM |
| WeissLaw LLP Investigates Abaxis Inc.
finance.yahoo.com - May 18 at 10:00 AM |
| Traders Buy High Volume of Call Options on Abaxis (ABAX)
www.americanbankingnews.com - May 18 at 7:41 AM |
| Reviewing OYO Geospace (GEOS) and Abaxis (ABAX)
www.americanbankingnews.com - May 17 at 5:10 PM |
| Abaxis (ABAX) Upgraded at ValuEngine
www.americanbankingnews.com - May 17 at 4:17 PM |
| SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Abaxis, Inc. - ABAX
finance.yahoo.com - May 17 at 9:37 AM |
 | Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
www.zacks.com - May 17 at 9:37 AM |
| Abaxis (ABAX) Upgraded to Neutral by Credit Suisse Group
www.americanbankingnews.com - May 16 at 6:07 PM |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Abaxis, Inc.
finance.yahoo.com - May 16 at 4:34 PM |
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Abaxis, Inc. (ABAX) on Behalf of Stockholders and Encourages Investors to Contact the Firm
www.businesswire.com - May 16 at 4:34 PM |
 | REFILE-UPDATE 5-Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln
www.cnbc.com - May 16 at 4:34 PM |
| Abaxis (ABAX) Downgraded by Sidoti
www.americanbankingnews.com - May 16 at 10:30 AM |
 | Zoetis to Buy Veterinary-Diagnostics Company Abaxis for $2 Billion
www.wsj.com - May 16 at 9:37 AM |
| Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln
finance.yahoo.com - May 16 at 9:37 AM |
 | BRIEF-Zoetis Says Upon Deal Termination By Abaxis Or Co, Termination Fee Of $70 Mln May Be Payable By Abaxis
www.reuters.com - May 16 at 9:37 AM |
 | Zoetis To Buy Abaxis In $2 Billion Deal
www.msn.com - May 16 at 9:37 AM |
| Zoetis to Acquire Abaxis, a Leading Global Provider of Veterinary Point-of-Care Diagnostic Instruments
finance.yahoo.com - May 16 at 9:37 AM |
 | Zoetis to buy veterinary diagnostics company Abaxis for $2bn
www.ft.com - May 16 at 9:37 AM |
| [$$] Zoetis to Buy Abaxis for $2 Billion
finance.yahoo.com - May 16 at 9:36 AM |
| Abaxis (ABAX) Alert: Johnson Fistel Investigates Proposed Sale of Abaxis, Inc.; Are Shareholders Getting a Fair Deal?
finance.yahoo.com - May 16 at 9:36 AM |
| Abaxis (ABAX) Director Sells $408,360.00 in Stock
www.americanbankingnews.com - May 10 at 7:54 PM |
| Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference and the UBS Global Healthcare Conference
finance.yahoo.com - May 10 at 9:34 AM |
 | Research Report Identifies Jaguar Animal Health, Dollar Tree, WPX Energy ...
globenewswire.com - May 7 at 4:42 PM |
| Abaxis (ABAX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 6 at 8:16 PM |
| Abaxis (ABAX) Expected to Announce Quarterly Sales of $67.84 Million
www.americanbankingnews.com - May 6 at 4:15 AM |
| Analyzing OYO Geospace (GEOS) & Abaxis (ABAX)
www.americanbankingnews.com - May 6 at 1:10 AM |
| Zacks: Brokerages Expect Abaxis (ABAX) to Announce $0.35 Earnings Per Share
www.americanbankingnews.com - May 4 at 11:30 AM |
Abaxis (NASDAQ:ABAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abaxis (NASDAQ:ABAX) Income Statement, Balance Sheet and Cash Flow Statement
Abaxis (NASDAQ ABAX) Stock Chart for Sunday, June, 17, 2018
Loading chart…
